Maternal plasma cell-free RNA as a predictive test for fetal lung maturation

Area of Science:

• Obstetrics and Gynecology
• Fetal Medicine
• Genomics

Background:

• Assessing fetal lung maturity is crucial for managing preterm birth and guiding antenatal steroid treatment.
• Current methods lack non-invasive and accurate fetal development assessment tools.
• Cell-free RNA (cfRNA) analysis offers a potential solution for evaluating fetal lung maturation.

Purpose of the Study:

• To analyze the expression of 21 cfRNA targets related to human fetal lung maturation.
• To validate cfRNA analysis as a predictor of fetal lung maturity in maternal plasma.
• To explore the potential of cfRNA as a clinical tool for optimizing antenatal steroid administration.

Main Methods:

• Utilized a preterm sheep model with antenatal steroid administration (dexamethasone, betamethasone) or saline control.
• Analyzed cfRNA targets in maternal and fetal sheep plasma, comparing with fetal lung mRNA expression.
• Validated findings in human maternal plasma across trimesters and in sheep models with endotoxin exposure.

Main Results:

• Maternal plasma cfRNA analysis accurately predicted fetal lung maturation across various models (AUCs ranging from 0.93 to 1).
• cfRNA expression patterns in sheep mirrored fetal lung tissue mRNA, especially after dexamethasone treatment.
• Human maternal plasma cfRNA demonstrated high predictive value for fetal lung maturity across trimesters (AUCs 0.96-1).

Conclusions:

• Maternal plasma cfRNA analysis is a highly predictive, non-invasive method for assessing fetal lung maturation.
• This technology can inform clinical decisions regarding antenatal steroid use in pregnancies at risk of preterm birth.
• Further development could lead to a cost-effective tool for optimizing fetal lung development management.